Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The International Society of Dermatology (ISD) stands at the forefront of advancing global skin health through education, collaboration and outreach.1 Established with a mission to bridge disparities in dermatological care worldwide, the ISD has become a vital hub for connecting the dermatology community, encouraging scientific exchange and promoting equitable access to dermatologic knowledge and services. […]

Alopecia Areata

An Introduction to Alopecia areata

Alopecia areata (AA) is an inflammatory cause of unpredictable, patchy hair loss that affects up to 2% of the population. Current treatment options for AA involve local steroid injections at the site of alopecia combined with topical retinoids; however, these are of limited efficacy and are associated with significant adverse effects. Recent insights into the pathogenesis of AA have allowed the development of novel treatment options, in particular, Janus kinase (JAK) inhibitors and cytokine-targeted therapy. There have also been reports of hair regrowth following treatment with platelet-rich plasma, stem cell-based therapy approaches and faecal microbiota transplantation.

Our supporting partners do not constitute an endorsement of the content on this page.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking ...

35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Maryanne M Senna, Dr Anna Waśkiel-Burnat

Watch two expert dermatologists discuss AA, focusing on issues related to disease severity, pathophysiology and treatment with JAK inhibitors.

Close Popup